TNKASE (tenecteplase) - Roche, Boehringer Ingelheim
Activase (alteplase) - Roche, Boehringer Ingelheim, Kyowa Kirin, Tanabe Pharma
A Bayesian conditional probability simulation framework for pre-hospital stroke transport decisions in the tenecteplase era: decision boundaries, global sensitivity, and stochastic dominance. (PubMed, Front Neurol) - Sep 6, 2026 - "Two recent developments motivate an updated treatment: the shift of the intravenous thrombolysis standard from alteplase to tenecteplase, and the maturation of randomised evidence on DS-versus-MS triage and on MSU effectiveness. The framework is open and reproducible and depends only on published trial-level evidence. It is presented as a decision-analytic and hypothesis-generating tool for structuring the tenecteplase-era triage question rather than as a validated operational triage rule, and prospective calibration against region-specific stroke-system data would be required before any deployment." 
Journal • Cardiovascular • Ischemic stroke
http://www.ncbi.nlm.nih.gov/pubmed/42698453
 
Sep 6, 2026
 
Prev Next